Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Summary

This is a Phase II study of intravenous Bevacizumab in patients with pathologically confirmed nonresectable primary adrenocortical cancer (ACC). Patients must have received no prior therapy. They will receive Bevacizumab as a single agent every 2 weeks intravenously until disease progression. This study will be open at multiple sites.

Timeline

Start

2007-05

Primary completion

—

Completion

2009-09

Outcome

Outcome not reported

Stopped (Enrollment): “unable to enroll subjects into the study”

Drugs

Indications